Shilpa Medicare Limited — Investor Meet, 19-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Shilpa Medicare reported its highest ever quarterly EBITDA of INR110 Cr (+21% YoY) and Q2 revenues of INR372 Cr (+7% YoY). The financial results for the half-year saw PAT surpass the full-year FY25 figure. Management noted strong momentum, focusing on asset utilization across complex API, Formulation, and Biologics segments. Key developments include the launch of NorUDCA in India with global expansion plans and commercial supplies for an NCE program starting Q4 FY26. The company is advancing multiple complex products like Semaglutide and Aflibercept. Outlook remains positive, aiming for sustained profitability and improved ROCE through a strong pipeline and strategic execution.